News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mentor Corporation (MNTR) Capital Chairman Highlights $0.91/Share Non-GAAP Gains from Cancer Portfolio Appreciation


1/25/2010 12:13:07 PM

SAN DIEGO--(BUSINESS WIRE)--Mentor Capital, Inc. (Pink Sheets:MNTR) Chairman, in his 2009 Letter to Shareholders, outlined $0.91/sh gains. On a mark-to-market basis Mentor Capital projected earnings per basic outstanding share for 2009 would be approximately 91 cents per share. On a fully diluted basis, Company mark-to-market earnings would be approximately 29 cents per average share equivalent for the year. The majority of Mentor Capital mark-to-market gains, used internally to judge management performance, are in the appreciation of cancer immunotherapy stock holdings. On a GAAP basis, these gains will not be recognized until later. Not counting these portfolio gains, the GAAP earnings per basic share, on a more precise but still not audited basis, would be an 18 cent loss, generally reflecting Company operating expenses.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES